Shares of Syndax Pharmaceuticals have tumbled 17% after a phase 2 flop | Syndax and Incyte are cutting their idiopathic ...

Since the drug’s approval and launch earlier this year, J&J has recorded more than 20,000 patient starts on Icotyde, funneled ...

Drug-device maker Kaléo has secured a federal contract worth $96.1 million, enlisting in an effort to bolster U.S. biodefense ...

UCB is encouraging people with immunology-driven diseases such as hidradenitis suppurativa (HS), plaque psoriasis and ...

Rather than another instance of on-shoring enthusiasm, ARPA-H’s personalized RNA drug production network project should be ...

One in two women is unaware that hormonal fluctuations during perimenopause and menopause can affect their skin, a Galderma ...

Roughly half a year after the close of its deal to acquire Bayer spinout AiCurus, Asahi Kasei’s $920 million bet has paid off ...

Less than four years after returning to Bausch + Lomb to lead the eye health company following its split from Bausch Health, ...

Life sciences organizations have invested heavily in data and analytics, yet timely decision making remains a challenge. | ...

Most manufacturers know Inmar for pharmacy returns and consumer drug takeback programs. | Emily Welker explains how retail ...

The pharmaceutical patient journey has always been complex, but today's media environment presents more touchpoints than ever ...

Everyone talks about AI as an efficiency engine. But according to /prompt CEO Paul Dyer, the technology’s greatest impact may ...